Health Condition 1: G933- Postviral fatigue syndrome
Conditions
Interventions
Intervention1: CelWel Product Administration: CelWel product-containing natural extracts of tinospora cordifolia, a common herb that goes with the local name of guduchi, combined with pepper extracts
Sponsors
Carmel Research Consultancy Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male and female subjects over 18 years of age 2.Willingness to follow the protocol requirements as evidenced by written, informed consent. 3.Mentally, physically and legally eligible to give informed consent 4.Willingness to complete study questionnaires. 5.Able to use a smartphone and an mobile application for delivering feedback every week on symptoms
Exclusion criteria
Exclusion criteria: 1.Patients with pre-existing or other severe systemic diseases that necessitate long-term medication. 2.Any vascular or systemic disorder which could affect any of the efficacy assessments. 3.Subjects received other medication (anti-viral) within 36 hours before entry into the study. 4.Evidence of significant uncontrolled co-morbid disease, which in the investigators opinion, would jeopardize patient participation. 5.Patients hospitalized or requiring oxygen support
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in fatigue severity scale (FSS) score from baseline to different assessment points [Duration: 4 weeks]Timepoint: At day 0, day 7, day 14, day 21 & day 28. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Changes in the COVID-19 Yorkshire Rehabilitation Screening (C19-YRS) score on physical functions & structures, activity limitations, and personal factors from baseline to different assessment points. 2.If any incidence of adverse events (AEs) during treatment period. Timepoint: At day 0, day 7, day 14, day 21 & day 28. | — |
Countries
India
Contacts
Public ContactProf Dr Alben Sigamani
Carmel Research Consultancy Pvt Ltd
Outcome results
None listed